Alaska Air Group, Inc.
$9.91B- Market cap
- $4.69B
- Debt
- +$5.85B
- Cash
- −$627.00M
Capital structure 45% equity / 55% debt · EV / Revenue 0.70x · EV / EBITDA 19.59x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 ·
Decision snapshot: ALK stock price vs BLUE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BLUE's multiple
Needs BLUE P/E.
Implied fair value · at ALK's multiple
Needs EPS (TTM) is negative.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALK FY 2025 (ended Dec 31, 2025) · BLUE FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 45% equity / 55% debt · EV / Revenue 0.70x · EV / EBITDA 19.59x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALASKA AIR GROUP, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
bluebird bio, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.42x
-2.27x
Net debt / EBITDA
Leverage against operating earnings
10.32x
-0.04x
Cash and equivalents
Liquid reserves on the balance sheet
$627.00M
$62.31M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
DELTA AIR LINES, INC.
ALK vs DAL
American Airlines Group Inc.
ALK vs AAL
SOUTHWEST AIRLINES CO
ALK vs LUV
JETBLUE AIRWAYS CORP
ALK vs JBLU
Allegiant Travel CO
ALK vs ALGT
BIOMARIN PHARMACEUTICAL INC
ALK vs BMRN
Editas Medicine, Inc.
ALK vs EDIT
SANGAMO THERAPEUTICS, INC
ALK vs SGMO
Intellia Therapeutics, Inc.
ALK vs NTLA
$5.85B
$71.51M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.